India, May 1 -- Esperion Therapeutics (ESPR), a biopharmaceutical company, on Friday announced that it has agreed to be acquired by funds managed by healthcare investment firm ARCHIMED in a deal valued at up to $1.1 billion.
Under the definitive agreement, Esperion shareholders will receive $3.16 per share in cash at closing, plus one non-tradeable contingent value right entitling holders to up to $100 million in milestone payments.
The upfront cash represents a 58 percent premium to Esperion's closing share price on April 30.
The contingent payments are tied to future U.S. net sales.
Holders would receive up to $40 million based on 2027 sales of bempedoic acid products including NEXLETOL and NEXLIZET - if sales exceed $350 million, or ...